MX2021008646A - Acidos carboxilicos policiclicos sustituidos, analogos de los mismos, y metodos para utilizar los mismos. - Google Patents
Acidos carboxilicos policiclicos sustituidos, analogos de los mismos, y metodos para utilizar los mismos.Info
- Publication number
- MX2021008646A MX2021008646A MX2021008646A MX2021008646A MX2021008646A MX 2021008646 A MX2021008646 A MX 2021008646A MX 2021008646 A MX2021008646 A MX 2021008646A MX 2021008646 A MX2021008646 A MX 2021008646A MX 2021008646 A MX2021008646 A MX 2021008646A
- Authority
- MX
- Mexico
- Prior art keywords
- analogues
- carboxylic acids
- same
- substituted polycyclic
- methods
- Prior art date
Links
- -1 polycyclic carboxylic acids Chemical class 0.000 title abstract 2
- 208000037262 Hepatitis delta Diseases 0.000 abstract 2
- 241000724709 Hepatitis delta virus Species 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962793578P | 2019-01-17 | 2019-01-17 | |
| PCT/US2020/013701 WO2020150366A1 (en) | 2019-01-17 | 2020-01-15 | Substituted polycyclic carboxylic acids, analogues thereof, and methods using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008646A true MX2021008646A (es) | 2021-10-26 |
Family
ID=71613992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008646A MX2021008646A (es) | 2019-01-17 | 2020-01-15 | Acidos carboxilicos policiclicos sustituidos, analogos de los mismos, y metodos para utilizar los mismos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220125771A1 (https=) |
| EP (1) | EP3911653A4 (https=) |
| JP (1) | JP2022518456A (https=) |
| KR (1) | KR20210121044A (https=) |
| CN (1) | CN113825756A (https=) |
| AU (1) | AU2020208371A1 (https=) |
| BR (1) | BR112021014079A2 (https=) |
| CA (1) | CA3126102A1 (https=) |
| EA (1) | EA202191967A1 (https=) |
| IL (1) | IL284845A (https=) |
| MX (1) | MX2021008646A (https=) |
| PH (1) | PH12021551718A1 (https=) |
| SG (1) | SG11202106965RA (https=) |
| TW (1) | TW202033523A (https=) |
| WO (1) | WO2020150366A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202001685TA (en) | 2017-08-28 | 2020-03-30 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| TWI801517B (zh) | 2018-03-12 | 2023-05-11 | 加拿大商愛彼特生物製藥公司 | 經取代的2-吡啶酮三環化合物、其類似物及其使用方法 |
| CN110862390B (zh) | 2018-08-28 | 2023-05-09 | 广东东阳光药业有限公司 | 稠合三环类化合物及其在药物中的应用 |
| JP2022500466A (ja) | 2018-09-21 | 2022-01-04 | エナンタ ファーマシューティカルズ インコーポレイテッド | 抗ウイルス剤としての官能化複素環 |
| CN110964023B (zh) | 2018-09-30 | 2022-12-27 | 广东东阳光药业有限公司 | 稠合四环类化合物及其在药物中的应用 |
| IL283190B2 (en) | 2018-11-21 | 2025-08-01 | Enanta Pharm Inc | Functionalized heterocycles as antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) * | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| TW202304914A (zh) * | 2021-04-05 | 2023-02-01 | 加拿大商愛彼特生物製藥公司 | 經取代之四環羧酸、其類似物及使用其之方法 |
| TW202412791A (zh) * | 2022-08-16 | 2024-04-01 | 加拿大商愛彼特生物製藥公司 | 經取代之四環羧酸及其類似物的合成 |
| CN115819200B (zh) * | 2022-11-28 | 2023-08-29 | 辽宁科技学院 | 一种苊醌的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| WO2014121416A1 (en) * | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
| JP6506880B2 (ja) * | 2015-07-27 | 2019-04-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウィルス感染症の治療および予防のための新規な四環式４−オキソ−ピリジン−３−カルボン酸誘導体 |
| US20200270265A1 (en) * | 2016-02-19 | 2020-08-27 | Novartis Ag | Tetracyclic pyridone compounds as antivirals |
| WO2018073753A1 (en) * | 2016-10-18 | 2018-04-26 | Novartis Ag | Fused tetracyclic pyridone compounds as antivirals |
| AR111419A1 (es) * | 2017-04-27 | 2019-07-10 | Novartis Ag | Compuestos fusionados de indazol piridona como antivirales |
| CN110066278B (zh) * | 2017-06-01 | 2021-06-08 | 广东东阳光药业有限公司 | 稠合三环类化合物及其在药物中的应用 |
| TWI815887B (zh) * | 2018-05-15 | 2023-09-21 | 美商愛彼特生物製藥股份有限公司 | 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法 |
-
2020
- 2020-01-10 TW TW109100934A patent/TW202033523A/zh unknown
- 2020-01-15 MX MX2021008646A patent/MX2021008646A/es unknown
- 2020-01-15 PH PH1/2021/551718A patent/PH12021551718A1/en unknown
- 2020-01-15 WO PCT/US2020/013701 patent/WO2020150366A1/en not_active Ceased
- 2020-01-15 AU AU2020208371A patent/AU2020208371A1/en not_active Abandoned
- 2020-01-15 EP EP20742028.2A patent/EP3911653A4/en not_active Withdrawn
- 2020-01-15 JP JP2021541219A patent/JP2022518456A/ja active Pending
- 2020-01-15 CN CN202080016321.4A patent/CN113825756A/zh active Pending
- 2020-01-15 CA CA3126102A patent/CA3126102A1/en active Pending
- 2020-01-15 KR KR1020217023731A patent/KR20210121044A/ko not_active Ceased
- 2020-01-15 EA EA202191967A patent/EA202191967A1/ru unknown
- 2020-01-15 SG SG11202106965RA patent/SG11202106965RA/en unknown
- 2020-01-15 US US17/423,151 patent/US20220125771A1/en not_active Abandoned
- 2020-01-15 BR BR112021014079-4A patent/BR112021014079A2/pt not_active IP Right Cessation
-
2021
- 2021-07-14 IL IL284845A patent/IL284845A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021551718A1 (en) | 2022-03-28 |
| IL284845A (en) | 2021-08-31 |
| JP2022518456A (ja) | 2022-03-15 |
| AU2020208371A1 (en) | 2021-07-15 |
| EA202191967A1 (ru) | 2021-10-07 |
| EP3911653A4 (en) | 2022-11-02 |
| EP3911653A1 (en) | 2021-11-24 |
| SG11202106965RA (en) | 2021-08-30 |
| TW202033523A (zh) | 2020-09-16 |
| KR20210121044A (ko) | 2021-10-07 |
| CN113825756A (zh) | 2021-12-21 |
| BR112021014079A2 (pt) | 2021-09-21 |
| WO2020150366A1 (en) | 2020-07-23 |
| US20220125771A1 (en) | 2022-04-28 |
| CA3126102A1 (en) | 2020-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551718A1 (en) | Substituted polycyclic carboxylic acids, analogues thereof, and methods using same | |
| ZA202006378B (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | |
| PH12018550148A1 (en) | Hepatitis b antiviral agents | |
| PH12018550201A1 (en) | Hepatitis b antiviral agents | |
| PH12020550065A1 (en) | Hepatitis b antiviral agents | |
| PH12016501631A1 (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| PH12018550150A1 (en) | Elimination of hepatitis b virus with antiviral agents | |
| GEP20227374B (en) | Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv) | |
| WO2019143902A3 (en) | Substituted heterocycles as antiviral agents | |
| EA202091113A1 (ru) | Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv) | |
| WO2019222238A3 (en) | Substituted 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same | |
| EA201992771A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
| MX388482B (es) | Métodos para tratar el virus de la hepatitis c. | |
| PH12021550632A1 (en) | Monomer and multimeric anti-hbv agents | |
| PH12017501687A1 (en) | Inhibitors of hepatitis c virus polymerase | |
| ZA202106097B (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| JOP20190214A1 (ar) | ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها | |
| MX2022014242A (es) | Amidas tricíclicas sustituidas, análogos de las mismas y métodos que usan las mismas. | |
| PH12020550549A1 (en) | Compositions for preventing or treating lupus | |
| EA201900320A1 (ru) | Пролекарство ингибитора ns5b hcv полимеразы, способ его получения и применения | |
| PH12021552755A1 (en) | Novel oxalyl piperazines active against the hepatitis b virus (hbv) | |
| EA202191634A1 (ru) | Замещенные арилметилмочевины и гетероарилметилмочевины, их аналоги и способы их применения | |
| MX2019011173A (es) | Compuesto que contiene silicio para la resistencia a la infeccion por el virus de la hepatitis c. | |
| PH12021552865A1 (en) | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus |